Annual Report

Overview

The report presents Mabpharm's 2023 consolidated revenue of 87,161 RMB'000 and highlights the commercialization of CMAB007 and CMAB008. It reports 347 employees, 18,934.79 MWh of total energy consumption, 8,076.56 ton of Scope 1 and Scope 2 greenhouse gas emissions, and zero work-related fatalities. ESG governance places the Board as the highest authority, with the Audit Committee responsible for day-to-day ESG management. The company also assessed 22 material ESG issues and contributed RMB257,000 plus 1,000 boxes of medicine to an autoimmune-disease patient aid project.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services